Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.77 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | HPGDS | O60760 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24975342 | 0.90 | HTT (0.61) | HTTALDH1A1LMNANPSR1KMT2A | |
| SCHEMBL29801153 | 0.90 | HTT (0.61) | HTTALDH1A1LMNANPSR1KMT2A | |
| SCHEMBL11628844 | 0.88 | HTT (1.00) | HTTALDH1A1LMNANPSR1KMT2A | |
| SCHEMBL29801317 | 0.85 | HTT (0.58) | HTTALDH1A1LMNANPSR1KMT2A | |
| SCHEMBL24976313 | 0.85 | HTT (0.58) | HTTALDH1A1LMNANPSR1KMT2A | |
| SCHEMBL24976698 | 0.85 | ALDH1A1 (0.58) | HTTALDH1A1LMNANPSR1KMT2A | |
| SCHEMBL29801122 | 0.84 | KMT2A (0.66) | HTTALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL24975530 | 0.84 | HPGDS (0.64) | HTTALDH1A1LMNAKMT2AHPGDS | |
| SCHEMBL24975558 | 0.84 | KMT2A (0.66) | HTTALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL29801099 | 0.84 | HPGDS (0.64) | HTTALDH1A1LMNAKMT2AHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023124-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023124-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, KIT, GLI1 | HTT 991/4885ALDH1A1 23/4885LMNA 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.